Millennium Management’s Kyntra Bio KYNB Stock Holding History

Millennium Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,876	Closed	-$329K	–	6255
2023 Q2	$329K	Buy	+4,876	New	+$2.02M	﹤0.01%	4821

Other funds holding KYNB

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management's KYNB Position: Q2 2025 in Review

Millennium Management sold out of Kyntra Bio (KYNB) in Q2 2025, closing a stake of 17,675 shares — an estimated $137K sold.

Millennium Management first reported a position in KYNB in Q4 2014 and held it in 36 quarters. The position peaked at $11.2M in Q1 2023. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.

Millennium Management reported no remaining Kyntra Bio position as of Q2 2025 after selling out during the quarter.
Millennium Management sold 17,675 Kyntra Bio shares in Q2 2025, an estimated $137K.
Millennium Management first reported a position in Kyntra Bio in Q4 2014 and held it in 36 quarters.
Millennium Management's Kyntra Bio position peaked at $11.2M in Q1 2023.
30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.